19 September 2022
News
Small Pharma Completes Enrollment In Phase IIa DMT-Assisted Psychotherapy Clinical Trial In Patients With Major Depressive Disorder
Dosing for primary endpoint now complete.
Investor Media
Check out the latest company media, insights, press, conferences and events around the world. Delve into all the content on specific topic areas such as Company Financials.
14 September 2022
News
Small Pharma Enters Into Automatic Share Purchase Plan
LONDON, September 13, 2022 (GLOBE NEWSWIRE) – Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the…
8 September 2022
Events & Conferences
Small Pharma To Participate In Upcoming September Investor Conferences
Small Pharma to participate in H.C. Wainwright and Jefferies conferences.
18 August 2022
News
Small Pharma Announces TSXV Approval of Normal Course Issuer Bid
The TSX Venture Exchange has accepted Small Pharma's application.
15 August 2022
News
Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study
Study will explore the interaction between SSRI antidepressants and SPL026.
3 August 2022
News
Canadian Patent Grant Strengthens Small Pharma’s International Position
Further Composition of Matter protection for SPL028.
26 July 2022
News
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy with Injectable Formulation
U.S. Patent Grant To Strengthen Small Pharma’s Dmt Patent Strategy With Injectable Formulation.
18 July 2022
News
George Tziras to succeed Peter Rands as Small Pharma Chief Executive Officer
George Tziras to succeed Peter Rands as Small Pharma Chief Executive Officer, with Peter Rands…
15 July 2022
News
Small Pharma Reports Fiscal First Quarter 2023 Highlights
Small Pharma reports fiscal first quarter 2023 highlights, as progress continues with multiple trials expected…
22 June 2022
Events & Conferences
Small Pharma to participate in the H. C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
Small Pharma to participate in the H. C. Wainwright 1st Annual Mental Health Conference on…